Bio-Rad, MJ Research to Stop Selling Real-Time PCR Machines in Germany; ABI Obtains Injunctions
By a GenomeWeb staff reporter
NEW YORK, June 23 (GenomeWeb News) - Applied Biosystems has obtained injunctions against Bio-Rad Laboratories, MJ Research, and MJ Research distributor Biozym in Germany, prohibiting these companies from manufacturing and selling thermal cyclers for real-time PCR, ABI said today.
The injunctions were issued by the German District Court in Düsseldorf. The court found that the defendants infringe a German patent corresponding to European Patent No. 872562, issued to ABI's parent company Applera in Septembrer 2002.
In April 2003, ABI obtained a similar injunction against Bio-Rad in Japan based on a Japanese patent.
[此贴子已经被作者于2004-6-26 16:46:34编辑过]
Bio-Rad Announces Agreement in Principle to Acquire MJ Research
HERCULES, CA, June 2, 2004 - Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research products and clinical diagnostics, announced today that it has signed a binding letter agreement which sets forth certain principal terms for the acquisition by Bio-Rad of MJ GeneWorks, Inc., and its subsidiaries for approximately $47 million in cash plus the assumption of certain liabilities of those companies. MJ GeneWorks is the parent company of MJ Research, Inc. of Waltham, Massachusetts, a biotechnology company that specializes in thermal cycling instrumentation and reagents used to amplify DNA. The acquisition is subject to completion of a definitive purchase agreement and necessary government approvals.
MJ Research, Inc. is a biotechnology company specializing in premium instruments and consumables used in modern biological research. MJ Research pioneered the use of Peltier-effect technology and has introduced a number of other innovations in the thermal-cycling field. MJ Research employs approximately 300 employees.
Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.
Various statements made within this press release may constitute "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.
For more information contact:
Christine Tsingos, Vice President and Chief Financial Officer, or
Ron Hutton, Treasurer
Bio-Rad Laboratories, Inc.
Phone: 510-724-7000
E-mail: investor_relations@bio-rad.com